Overview
Ashutosh Chilkoti is the Alan L. Kaganov Professor of Biomedical Engineering and Chair of the Department of Biomedical Engineering at Duke University.
My research in biomolecular engineering and biointerface science focuses on the development of new molecular tools and technologies that borrow from molecular biology, protein engineering, polymer chemistry and surface science that we then exploit for the development of applications that span the range from bioseparations, plasmonic biosensors, low-cost clinical diagnostics, and drug delivery.
Current Appointments & Affiliations
Alan L. Kaganov Distinguished Professor of Biomedical Engineering
·
2016 - Present
Biomedical Engineering,
Pratt School of Engineering
Professor of Biomedical Engineering
·
2006 - Present
Biomedical Engineering,
Pratt School of Engineering
Professor in the Department of Chemistry
·
2009 - Present
Chemistry,
Trinity College of Arts & Sciences
Research Professor of Global Health
·
2020 - Present
Duke Global Health Institute,
University Institutes and Centers
Professor in the Thomas Lord Department of Mechanical Engineering and Materials Science
·
2022 - Present
Thomas Lord Department of Mechanical Engineering and Materials Science,
Pratt School of Engineering
Member of the Duke Cancer Institute
·
1996 - Present
Duke Cancer Institute,
Institutes and Centers
Core Faculty in Innovation & Entrepreneurship
·
2018 - Present
Duke Innovation & Entrepreneurship,
University Initiatives & Academic Support Units
Recent Publications
Synthetic biomolecular condensates enhance translation from a target mRNA in living cells.
Journal Article Nat Chem · March 2025 Biomolecular condensates composed of proteins and RNA are one approach by which cells regulate post-transcriptional gene expression. Their formation typically involves the phase separation of intrinsically disordered proteins with a target mRNA, sequesteri ... Full text Link to item CiteBinding Strength, Not Valency, Dictates Accumulation and Penetration of Affinity Targeted Macromolecules into Solid Tumors.
Journal Article Biomacromolecules · January 2025 The efficacy of tumor-targeted therapeutics, engineered to engage specific cellular receptors to promote accumulation and penetration, is strongly influenced by the carrier's affinity for its target and the valency of binding molecules incorporated into th ... Full text CitePreclinical Development of a Genetically Engineered Albumin-Binding Nanoparticle of Paclitaxel.
Journal Article Small science · November 2024 Nab-paclitaxel (Abraxane), an albumin-bound solvent-free paclitaxel (PTX) formulation that takes advantage of the endogenous albumin transport pathway, is the current gold standard for treatment of solid tumors with PTX. However, nab-paclitaxel has several ... Full text CiteRecent Grants
Breast Cancer Diagnostic Kit to Improve Early Diagnosis in Uganda
ResearchPrincipal Investigator · Awarded by Vanderbilt University Medical Center · 2024 - 2029Development, Clinical Validation, and Readiness for Implementation of a Novel Mp1p D4 Point of Care Test for Rapid Diagnosis of Talaromycosis
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2023 - 2028Scale up and toxicity studies of POEGMA-Uricase
ResearchPrincipal Investigator · Awarded by Gateway Bio, Inc. · 2024 - 2027View All Grants
Education, Training & Certifications
University of Washington ·
1991
Ph.D.